Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Inclusion criteria

• Males or females
• Control (Adult) group: aged between 18 and 65 years (inclusive)
• Elderly group: aged > 65 years (includes subjects 1 day or more beyond the 65th birthday)
• Able to give signed informed consent
• BMI 27-45 kg/m2, inclusive 6. Eligible male and female subjects must agree not to participate in a conception process (i.e. active attempt to become pregnant or to impregnate, egg or sperm donation, in vitro fertilization).
• Considered to be in stable health in the opinion of the Investigator

Exclusion criteria

• Prior participation in any study of lorcaserin.
• Clinically significant new illness in the 1 month before screening
• Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
• History of any of the following cardiovascular conditions:

• Myocardial infarction (diagnosed by cardiac enzyme[s] and/or diagnostic ECG), cerebral vascular accident (CVA), transient ischemic attack (TIA) or reversible ischemic neurologic deficit (RIND) within 6 months of screening
• Cardiac arrhythmia requiring initiation of new medical or surgical treatment within 6 months of screening (stable medical therapy for > 6 months, pacemakers and/or defibrillators implanted > 6 months prior to screening are acceptable)
• Unstable angina
• History of pulmonary artery hypertension
• Positive result of HIV, hepatitis B or hepatitis C screens
• Initiation of a new prescription medication within 1 month prior to screening with the following exceptions:
• Use of SSRIs, SNRIs, and other medications must meet washout period.
• Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening